Business Standard

Monday, December 23, 2024 | 12:16 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Strong specialty sales and volumes keep it sunny for Sun Pharma

Rerating on the cards; the domestic business is expected to outperform

Sun Pharma
Premium

Ram Prasad Sahu Mumbai
Growth momentum for its US specialty drug portfolio, acquisitions, and outperformance in the domestic pharma market may sustain the returns trajectory of the country’s largest drugmaker, Sun Pharmaceutical Industries (Sun Pharma). The stock is the second-biggest gainer among the Nifty Pharma constituents with returns of 56 per cent over the past year.

Even as its peers are facing high single-digit price erosion, the impact on Sun Pharma is less, given its focus on a specialty drug portfolio. Quarter-to-date sales and volumes remain strong for most of its key specialty products in the US market. Rahul Jeewani and Punit Pujara of IIFL

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in